Form 4: Anika Therapeutics EVP, CFO and Treasurer Stephen D. Griffin Reports Acquisition of Restricted Stock Units

Stephen D. Griffin, EVP, CFO, and Treasurer of Anika Therapeutics, reports the acquisition of restricted stock units (RSUs) on March 14, 2025.

Summary

• On March 14, 2025, Stephen D. Griffin, the EVP, CFO, and Treasurer of Anika Therapeutics, acquired 38,473 restricted stock units (RSUs).
• These RSUs vest in three equal annual installments starting March 14, 2026.
• Griffin also acquired 18,672 performance-based phantom RSUs, which will cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date.
• The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target).
• No shares shall vest for achievement under Threshold.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing regarding stock options, indicating a neutral sentiment.

Future Outlook

The RSUs represent a contingent right to receive shares of Anika Therapeutics' common stock or the cash equivalent, based on the company's discretion and vesting schedules.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and is common in publicly traded companies.

Stakeholder Impact

• The granting of RSUs aligns executive interests with shareholder value.

Key Dates